Analysts Anticipate Nuvectra Corporation (NVTR) Will Announce Earnings of -$1.16 Per Share
Analysts predict that Nuvectra Corporation (NASDAQ:NVTR) will announce ($1.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Nuvectra Corporation’s earnings. Nuvectra Corporation posted earnings of ($0.92) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 26.1%. The firm is expected to report its next earnings results on Wednesday, November 8th.
On average, analysts expect that Nuvectra Corporation will report full-year earnings of ($4.77) per share for the current year. For the next fiscal year, analysts expect that the business will report earnings of ($4.12) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Nuvectra Corporation.
Nuvectra Corporation (NASDAQ:NVTR) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($1.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.14) by $0.07. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $5.96 million. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The business’s quarterly revenue was up 188.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) EPS.
NVTR has been the subject of a number of research reports. TheStreet upgraded Nuvectra Corporation from a “d” rating to a “c-” rating in a research report on Monday, June 19th. ValuEngine upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Zacks Investment Research upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and set a $14.00 target price on shares of Nuvectra Corporation in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. Nuvectra Corporation currently has a consensus rating of “Hold” and an average target price of $13.00.
Shares of Nuvectra Corporation (NASDAQ:NVTR) traded up 0.65% during midday trading on Friday, hitting $14.00. 4,456 shares of the stock were exchanged. The firm’s 50-day moving average is $12.69 and its 200 day moving average is $12.69. Nuvectra Corporation has a 52-week low of $4.63 and a 52-week high of $15.00. The firm’s market cap is $149.79 million.
In related news, CEO Scott F. Drees purchased 10,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the completion of the transaction, the chief executive officer now directly owns 125,180 shares in the company, valued at $1,467,109.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.60% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Wolverine Trading LLC bought a new stake in Nuvectra Corporation in the second quarter worth $156,000. OxFORD Asset Management LLP bought a new stake in Nuvectra Corporation in the second quarter worth $154,000. Group One Trading L.P. bought a new stake in Nuvectra Corporation in the second quarter worth $167,000. Stifel Financial Corp lifted its position in Nuvectra Corporation by 6.2% in the second quarter. Stifel Financial Corp now owns 34,227 shares of the company’s stock worth $444,000 after buying an additional 1,999 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its position in Nuvectra Corporation by 4.2% in the second quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock worth $467,000 after buying an additional 1,434 shares during the last quarter. Institutional investors own 57.42% of the company’s stock.
About Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.